Sun Pharmaceutical Industries Inc: FDA regulatory signals
This page aggregates the United States FDA regulatory records that reference Sun Pharmaceutical Industries Inc in the datasets indexed by this site. Across the ingested data, Sun Pharmaceutical Industries Inc is associated with 9 recall record(s), 19 drug-shortage record(s), and 0 approval record(s). The most recent dated event attributed to this firm in the indexed data is a shortage record dated 2026-07-23. These counts are coverage-limited activity signals derived only from the specific FDA datasets indexed here. They are NOT quality ratings, reputational scores, or judgements about the firm or its products. A higher or lower count reflects how often a firm appears in these particular public records over the ingested window — nothing more. Recalls and shortages are routine parts of pharmaceutical regulation, and their presence here is an administrative fact, not an indication of wrongdoing or of product danger. Use this page as a finding aid to locate the underlying FDA records, then verify every detail against the official source. This page contains regulatory information only and offers no medical advice.
Signal summary
| Recall records | 9 |
|---|---|
| Shortage records | 19 |
| Approval records | 0 |
| Most recent record date | 2026-07-23 |
| Most recent record type | shortage |
These counts are not a quality rating. They are coverage-limited activity signals showing how often this firm appears in the indexed FDA recall and shortage records over the ingested window. They are not reputational scores or judgements about the firm or its products.
Recall records
- Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30 · Class III · 2026-07-08
- Perampanel CIII Tablets, 6mg, Rx only, 30 Tablets, Mfd.by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 51672-4206-6 · Class II · 2026-07-01
- Budesonide Inhalation Suspension, 1mg/2mL, 30 x 2 mL Sterile Single-Dose Ampules (5 Single-Dose Ampules per pouch, 6 pouches per carton, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Baska Ujeti Road, Ujeti Halol-289350, Gujarat, India, NDC 47335-633-49. · Class II · 2026-06-17
- DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, NDC 72603-200-01. · Class I · 2026-06-17
- Xyvona (levorphanol tartrate tablets), 2mg, 100 Tablets, Rx only, Forte BioPharma, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901, Distributed by: Fort Bio-Pharma, LLC., Las Vegas, NV 89113, NDC 72245-762-10 · Class II · 2026-06-10
- Xyvona (levorphanol tartrate tablets), 3mg, 100 Tablets, Rx only, Forte BioPharma, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901, Distributed by: Fort Bio-Pharma, LLC., Las Vegas, NV 89113, NDC 72245-058-10 · Class II · 2026-06-10
- Fluocinonide, USP, 0.05% Cream, 30g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-2. · Class II · 2026-04-22
- Fluocinonide, USP, 0.05% Cream, 60g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-3. · Class II · 2026-04-22
- Fluocinonide, USP, 0.05% Cream, 15g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-1 · Class II · 2026-04-22
Shortage records
- Lisdexamfetamine Dimesylate Capsule · Current · 2026-07-23
- Methylphenidate Hydrochloride Tablet, Extended Release · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Capsule · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Tablet, Chewable · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Capsule · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Tablet, Chewable · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Tablet, Chewable · Current · 2026-07-23
- Methylphenidate Hydrochloride Tablet, Extended Release · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Capsule · Current · 2026-07-23
- Lisdexamfetamine Dimesylate Capsule · Current · 2026-07-23
Source limitations
This page is built only from the FDA recall and shortage records this site has ingested. It does not represent the firm's full regulatory history, its approvals, or any data held in sources not indexed here. The ingested window is finite and can lag the live FDA record, so counts and dates reflect a point in time. Every linked record points back to the verifiable official source; confirm details there. This page contains regulatory information only and offers no medical advice, no assessment of product safety, and no recommendation of any kind.
Source & provenance
- Official source
- https://open.fda.gov/apis/drug/enforcement/
- Source dataset
- openFDA (enforcement + shortages)
- Publication date
- Not available
- Ingested
- 2026-07-28
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.